Log in

Analysts Hate These 12 Stocks in 2020

Posted on Saturday, September 26th, 2020 by MarketBeat Staff
When a single Wall Street analyst downgrades one of your stocks, you might think they are just having a bad day or have an incorrect investment thesis. One downgrade typically won't have a significant impact on the price of one of your stocks, but what if a company was repeatedly downgraded by analysts over the last 30, 60 or 90 days? You would know something is seriously wrong.

Today, we are inviting you to take a free exclusive look at our up-to-the-minute list of 12 "Most Downgraded" stocks. These are true strong sell stocks. Analysts are abandoning them in droves and issuing rare downgrades and sell ratings. If any of these stocks are lurking around in your portfolio, seriously consider whether or not they still belong in your portfolio. .

#1 - Intel (NASDAQ:INTC)

Number of Downgrades: 20 (in the last 90 days)
Consensus Rating: Hold
Rating Score: 2.1
Ratings Breakdown: 16 Buy Ratings, 17 Hold Ratings, 10 Sell Ratings.
Consensus Price Target: $61.41 (23.0% Upside)

Intel logoIntel Corporation offers computing, networking, data storage, and communication solutions worldwide. It operates through Client Computing Group, Data Center Group, Internet of Things Group, Non-Volatile Memory Solutions Group, Programmable Solutions Group, and All Other segments. The company offers microprocessors, and system-on-chip and multichip packaging products. Read More 

Recent Recommendations for Intel:

  • Intel Co. (NASDAQ: INTC) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. (9/23/2020)
  • Intel Co. (NASDAQ: INTC) is now covered by analysts at Northland Securities. They set a "sell" rating and a $48.00 price target on the stock. (9/11/2020)
  • Intel Co. (NASDAQ: INTC) had its "buy" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $75.00 price target on the stock. (9/10/2020)
  • Intel Co. (NASDAQ: INTC) was upgraded by analysts at ValuEngine from a "strong sell" rating to a "sell" rating. (9/10/2020)
  • Intel Co. (NASDAQ: INTC) was upgraded by analysts at Standpoint Research from a "hold" rating to a "buy" rating. (9/8/2020)
  • Intel Co. (NASDAQ: INTC) had its "buy" rating re-affirmed by analysts at Credit Suisse Group AG. They now have a $70.00 price target on the stock. (8/24/2020)
  • Intel Co. (NASDAQ: INTC) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $63.00 price target on the stock. (8/10/2020)
  • Intel Co. (NASDAQ: INTC) had its "buy" rating re-affirmed by analysts at Tigress Financial. (7/30/2020)
  • Intel Co. (NASDAQ: INTC) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. (7/29/2020)
  • Intel Co. (NASDAQ: INTC) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. They now have a $53.00 price target on the stock. (7/27/2020)

#2 - Intercept Pharmaceuticals (NASDAQ:ICPT)

Number of Downgrades: 16 (in the last 90 days)
Consensus Rating: Hold
Rating Score: 2.3
Ratings Breakdown: 7 Buy Ratings, 17 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $75.61 (87.1% Upside)

Intercept Pharmaceuticals logoIntercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. Read More 

Recent Recommendations for Intercept Pharmaceuticals:

  • Intercept Pharmaceuticals Inc (NASDAQ: ICPT) had its "buy" rating re-affirmed by analysts at Wedbush. They now have a $140.00 price target on the stock. (8/28/2020)
  • Intercept Pharmaceuticals Inc (NASDAQ: ICPT) had its "hold" rating re-affirmed by analysts at Canaccord Genuity. They now have a $58.00 price target on the stock. (8/12/2020)
  • Intercept Pharmaceuticals Inc (NASDAQ: ICPT) had its "hold" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $57.00 price target on the stock. (8/11/2020)
  • Intercept Pharmaceuticals Inc (NASDAQ: ICPT) had its "hold" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $54.00 price target on the stock. (8/11/2020)
  • Intercept Pharmaceuticals Inc (NASDAQ: ICPT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $105.00 price target on the stock. (8/11/2020)
  • Intercept Pharmaceuticals Inc (NASDAQ: ICPT) is now covered by analysts at Needham & Company LLC. They set a "buy" rating and a $100.00 price target on the stock. (8/10/2020)
  • Intercept Pharmaceuticals Inc (NASDAQ: ICPT) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $97.00 price target on the stock. (8/10/2020)
  • Intercept Pharmaceuticals Inc (NASDAQ: ICPT) had its price target raised by analysts at Stifel Nicolaus from $51.00 to $56.00. They now have a "hold" rating on the stock. (8/10/2020)
  • Intercept Pharmaceuticals Inc (NASDAQ: ICPT) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $82.00 price target on the stock. (7/30/2020)
  • Intercept Pharmaceuticals Inc (NASDAQ: ICPT) was downgraded by analysts at JMP Securities from an "outperform" rating to a "market perform" rating. (7/21/2020)
#3 - Western Digital (NASDAQ:WDC)

Number of Downgrades: 16 (in the last 90 days)
Consensus Rating: Buy
Rating Score: 2.7
Ratings Breakdown: 20 Buy Ratings, 7 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $62.50 (62.5% Upside)

Western Digital logoWestern Digital Corporation develops, manufactures, and sells data storage devices and solutions worldwide. It offers client devices, including hard disk drives (HDDs) and solid state drives (SSDs) for computing devices, such as desktop and notebook PCs, security surveillance systems, gaming consoles, and set top boxes; flash-based embedded storage products for mobile phones, tablets, notebook PCs, and other portable and wearable devices, as well as automotive, IoT, industrial, and connected home applications; flash-based memory wafers; and embedded storage solutions and iNAND embedded flash products, such as multi-chip package solutions. Read More 

Recent Recommendations for Western Digital:

  • Western Digital Corp (NASDAQ: WDC) was upgraded by analysts at Cleveland Research from an "underperform" rating to a "neutral" rating. (9/23/2020)
  • Western Digital Corp (NASDAQ: WDC) was upgraded by analysts at Craig Hallum from a "hold" rating to a "buy" rating. They now have a $62.00 price target on the stock, up previously from $44.00. (9/23/2020)
  • Western Digital Corp (NASDAQ: WDC) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. (9/1/2020)
  • Western Digital Corp (NASDAQ: WDC) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. (8/22/2020)
  • Western Digital Corp (NASDAQ: WDC) had its price target lowered by analysts at Morgan Stanley from $63.00 to $58.50. They now have an "overweight" rating on the stock. (8/6/2020)
  • Western Digital Corp (NASDAQ: WDC) had its price target lowered by analysts at Wells Fargo & Company from $60.00 to $55.00. They now have an "overweight" rating on the stock. (8/6/2020)
  • Western Digital Corp (NASDAQ: WDC) had its price target lowered by analysts at Robert W. Baird from $75.00 to $50.00. They now have an "outperform" rating on the stock. (8/6/2020)
  • Western Digital Corp (NASDAQ: WDC) had its price target lowered by analysts at Royal Bank of Canada from $70.00 to $57.00. They now have an "outperform" rating on the stock. (8/6/2020)
  • Western Digital Corp (NASDAQ: WDC) had its price target lowered by analysts at Cowen Inc from $70.00 to $50.00. They now have an "outperform" rating on the stock. (8/6/2020)
  • Western Digital Corp (NASDAQ: WDC) was downgraded by analysts at Summit Insights from a "buy" rating to a "hold" rating. (8/6/2020)
#4 - LYFT (NASDAQ:LYFT)

Number of Downgrades: 16 (in the last 90 days)
Consensus Rating: Buy
Rating Score: 2.6
Ratings Breakdown: 22 Buy Ratings, 12 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $44.38 (61.2% Upside)

LYFT logoLyft, Inc operates a peer-to-peer marketplace for on-demand ridesharing in the United States and Canada. It provides Ridesharing Marketplace, which facilitates lead generation, billing and settlement, support, and related activities to enable drivers to provide their transportation services to riders. Read More 

Recent Recommendations for LYFT:

  • LYFT Inc (NASDAQ: LYFT) had its price target lowered by analysts at JPMorgan Chase & Co. from $41.00 to $38.00. They now have an "overweight" rating on the stock. (9/25/2020)
  • LYFT Inc (NASDAQ: LYFT) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. (9/25/2020)
  • LYFT Inc (NASDAQ: LYFT) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. (9/19/2020)
  • LYFT Inc (NASDAQ: LYFT) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. (9/4/2020)
  • LYFT Inc (NASDAQ: LYFT) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. (8/27/2020)
  • LYFT Inc (NASDAQ: LYFT) had its price target lowered by analysts at Citigroup Inc from $50.00 to $49.00. They now have a "buy" rating on the stock. (8/26/2020)
  • LYFT Inc (NASDAQ: LYFT) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. (8/21/2020)
  • LYFT Inc (NASDAQ: LYFT) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. (8/15/2020)
  • LYFT Inc (NASDAQ: LYFT) had its price target raised by analysts at Morgan Stanley from $31.00 to $34.00. They now have an "equal weight" rating on the stock. (8/13/2020)
  • LYFT Inc (NASDAQ: LYFT) had its price target lowered by analysts at Wedbush from $48.00 to $37.00. They now have an "outperform" rating on the stock. (8/13/2020)
#5 - Gilead Sciences (NASDAQ:GILD)

Number of Downgrades: 14 (in the last 90 days)
Consensus Rating: Hold
Rating Score: 2.3
Ratings Breakdown: 10 Buy Ratings, 15 Hold Ratings, 2 Sell Ratings.
Consensus Price Target: $78.93 (26.8% Upside)

Gilead Sciences logoGilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. Read More 

Recent Recommendations for Gilead Sciences:

  • Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at Royal Bank of Canada from $82.00 to $86.00. (9/18/2020)
  • Gilead Sciences, Inc. (NASDAQ: GILD) had its price target lowered by analysts at Royal Bank of Canada from $84.00 to $82.00. They now have an "outperform" rating on the stock. (9/15/2020)
  • Gilead Sciences, Inc. (NASDAQ: GILD) was upgraded by analysts at Maxim Group from a "hold" rating to a "buy" rating. They now have a $88.00 price target on the stock. (9/15/2020)
  • Gilead Sciences, Inc. (NASDAQ: GILD) had its price target lowered by analysts at SVB Leerink LLC from $94.00 to $88.00. They now have an "outperform" rating on the stock. (9/14/2020)
  • Gilead Sciences, Inc. (NASDAQ: GILD) had its "hold" rating re-affirmed by analysts at Raymond James. (9/14/2020)
  • Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at Oppenheimer Holdings Inc. from $90.00 to $105.00. They now have an "outperform" rating on the stock. (9/10/2020)
  • Gilead Sciences, Inc. (NASDAQ: GILD) had its price target lowered by analysts at Truist from $74.00 to $67.00. (8/20/2020)
  • Gilead Sciences, Inc. (NASDAQ: GILD) had its price target lowered by analysts at Piper Sandler from $85.00 to $83.00. They now have an "overweight" rating on the stock. (8/19/2020)
  • Gilead Sciences, Inc. (NASDAQ: GILD) had its price target lowered by analysts at Jefferies Financial Group Inc from $97.00 to $78.00. (8/19/2020)
  • Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at Wells Fargo & Company from $69.00 to $76.00. They now have an "equal weight" rating on the stock. (8/19/2020)
#6 - GALAPAGOS NV/S (NASDAQ:GLPG)

Number of Downgrades: 14 (in the last 90 days)
Consensus Rating: Hold
Rating Score: 2.1
Ratings Breakdown: 3 Buy Ratings, 10 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: $187.75 (34.9% Upside)

GALAPAGOS NV/S logoGalapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients. Read More 

Recent Recommendations for GALAPAGOS NV/S:

  • GALAPAGOS NV/S (NASDAQ: GLPG) had its "hold" rating re-affirmed by analysts at Stifel Nicolaus. (9/25/2020)
  • GALAPAGOS NV/S (NASDAQ: GLPG) had its "neutral" rating re-affirmed by analysts at JPMorgan Chase & Co.. (9/24/2020)
  • GALAPAGOS NV/S (NASDAQ: GLPG) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. (9/17/2020)
  • GALAPAGOS NV/S (NASDAQ: GLPG) had its "hold" rating re-affirmed by analysts at Stifel Nicolaus. (9/11/2020)
  • GALAPAGOS NV/S (NASDAQ: GLPG) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. (9/9/2020)
  • GALAPAGOS NV/S (NASDAQ: GLPG) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. (9/1/2020)
  • GALAPAGOS NV/S (NASDAQ: GLPG) was downgraded by analysts at Jefferies Financial Group Inc from a "buy" rating to a "hold" rating. (8/25/2020)
  • GALAPAGOS NV/S (NASDAQ: GLPG) was downgraded by analysts at HC Wainwright from a "buy" rating to a "neutral" rating. They now have a $123.00 price target on the stock, down previously from $270.00. (8/24/2020)
  • GALAPAGOS NV/S (NASDAQ: GLPG) had its price target lowered by analysts at Morgan Stanley from $221.00 to $158.00. They now have an "equal weight" rating on the stock. (8/21/2020)
  • GALAPAGOS NV/S (NASDAQ: GLPG) had its price target lowered by analysts at Bank of America Corp from $148.00 to $134.00. They now have an "underperform" rating on the stock. (8/21/2020)
#7 - Noble Energy (NYSE:NBL)

Number of Downgrades: 14 (in the last 90 days)
Consensus Rating: Hold
Rating Score: 2.3
Ratings Breakdown: 11 Buy Ratings, 13 Hold Ratings, 2 Sell Ratings.
Consensus Price Target: $14.55 (71.4% Upside)

Noble Energy logoNoble Energy, Inc, an independent energy company, engages in the acquisition, exploration, development, and production of crude oil, natural gas, and natural gas liquids worldwide. The company owns, operates, develops, and acquires domestic midstream infrastructure assets in the DJ and Delaware Basins. Read More 

Recent Recommendations for Noble Energy:

  • Noble Energy, Inc. (NYSE: NBL) was downgraded by analysts at Citigroup Inc from a "buy" rating to a "neutral" rating. (8/28/2020)
  • Noble Energy, Inc. (NYSE: NBL) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating. They now have a $11.00 price target on the stock. (8/21/2020)
  • Noble Energy, Inc. (NYSE: NBL) was downgraded by analysts at Wells Fargo & Company from an "overweight" rating to an "equal weight" rating. They now have a $13.00 price target on the stock. (8/13/2020)
  • Noble Energy, Inc. (NYSE: NBL) had its price target lowered by analysts at TD Securities from $10.25 to $10.10. They now have a "tender" rating on the stock. (8/4/2020)
  • Noble Energy, Inc. (NYSE: NBL) was downgraded by analysts at Truist Financial Corporation from a "buy" rating to a "hold" rating. (8/4/2020)
  • Noble Energy, Inc. (NYSE: NBL) was downgraded by analysts at Stifel Nicolaus from a "buy" rating to a "hold" rating. They now have a $11.00 price target on the stock, down previously from $26.00. (8/3/2020)
  • Noble Energy, Inc. (NYSE: NBL) had its price target lowered by analysts at SunTrust Banks, Inc. from $13.00 to $11.00. They now have a "buy" rating on the stock. (7/30/2020)
  • Noble Energy, Inc. (NYSE: NBL) was downgraded by analysts at US Capital Advisors from a "buy" rating to a "hold" rating. (7/22/2020)
  • Noble Energy, Inc. (NYSE: NBL) was downgraded by analysts at Argus from a "buy" rating to a "sell" rating. (7/22/2020)
  • Noble Energy, Inc. (NYSE: NBL) was downgraded by analysts at TD Securities to a "buy" rating. They now have a $10.25 price target on the stock. (7/21/2020)
#8 - Phillips 66 (NYSE:PSX)

Number of Downgrades: 13 (in the last 90 days)
Consensus Rating: Buy
Rating Score: 2.9
Ratings Breakdown: 15 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $80.44 (52.1% Upside)

Phillips 66 logoPhillips 66 operates as an energy manufacturing and logistics company. It operates through four segments: Midstream, Chemicals, Refining, and Marketing and Specialties (M&S). The Midstream segment transports crude oil and other feedstocks; delivers refined products to market; provides terminaling and storage services for crude oil and petroleum products; transports, stores, fractionates, exports, and markets natural gas liquids; provides other fee-based processing services; and gathers, processes, transports, and markets natural gas. Read More 

Recent Recommendations for Phillips 66:

  • Phillips 66 (NYSE: PSX) had its price target lowered by analysts at Raymond James from $75.00 to $69.00. They now have an "outperform" rating on the stock. (9/18/2020)
  • Phillips 66 (NYSE: PSX) had its price target lowered by analysts at JPMorgan Chase & Co. from $79.00 to $75.00. They now have an "overweight" rating on the stock. (9/11/2020)
  • Phillips 66 (NYSE: PSX) had its price target lowered by analysts at Piper Sandler from $87.00 to $84.00. They now have an "overweight" rating on the stock. (9/9/2020)
  • Phillips 66 (NYSE: PSX) had its price target lowered by analysts at Raymond James from $80.00 to $75.00. They now have an "outperform" rating on the stock. (8/25/2020)
  • Phillips 66 (NYSE: PSX) had its price target lowered by analysts at Morgan Stanley from $90.00 to $82.00. They now have an "overweight" rating on the stock. (8/11/2020)
  • Phillips 66 (NYSE: PSX) had its "buy" rating re-affirmed by analysts at Bank of America Corp. They now have a $100.00 price target on the stock. (8/3/2020)
  • Phillips 66 (NYSE: PSX) had its price target lowered by analysts at Piper Sandler from $91.00 to $87.00. They now have an "overweight" rating on the stock. (7/24/2020)
  • Phillips 66 (NYSE: PSX) had its price target lowered by analysts at Mizuho from $95.00 to $92.00. They now have a "buy" rating on the stock. (7/22/2020)
  • Phillips 66 (NYSE: PSX) was downgraded by analysts at Wells Fargo & Company from an "overweight" rating to an "equal weight" rating. They now have a $34.00 price target on the stock. (7/22/2020)
  • Phillips 66 (NYSE: PSX) was upgraded by analysts at Jefferies Financial Group Inc from a "hold" rating to a "buy" rating. They now have a $73.00 price target on the stock. (7/20/2020)
#9 - Illumina (NASDAQ:ILMN)

Number of Downgrades: 13 (in the last 90 days)
Consensus Rating: Hold
Rating Score: 2.2
Ratings Breakdown: 7 Buy Ratings, 8 Hold Ratings, 3 Sell Ratings.
Consensus Price Target: $325.39 (8.5% Upside)

Illumina logoIllumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array. Read More 

Recent Recommendations for Illumina:

  • Illumina, Inc. (NASDAQ: ILMN) had its price target lowered by analysts at Canaccord Genuity from $350.00 to $300.00. They now have a "hold" rating on the stock. (9/22/2020)
  • Illumina, Inc. (NASDAQ: ILMN) had its price target lowered by analysts at Robert W. Baird from $335.00 to $281.00. They now have a "neutral" rating on the stock. (9/22/2020)
  • Illumina, Inc. (NASDAQ: ILMN) had its price target lowered by analysts at SVB Leerink LLC from $360.00 to $315.00. They now have an "outperform" rating on the stock. (9/22/2020)
  • Illumina, Inc. (NASDAQ: ILMN) was downgraded by analysts at Stifel Nicolaus from a "buy" rating to a "hold" rating. They now have a $280.00 price target on the stock, down previously from $380.00. (9/22/2020)
  • Illumina, Inc. (NASDAQ: ILMN) was downgraded by analysts at UBS Group AG from a "buy" rating to a "neutral" rating. They now have a $285.00 price target on the stock, down previously from $390.00. (9/22/2020)
  • Illumina, Inc. (NASDAQ: ILMN) was downgraded by analysts at JPMorgan Chase & Co. from an "overweight" rating to a "neutral" rating. They now have a $280.00 price target on the stock, down previously from $390.00. (9/21/2020)
  • Illumina, Inc. (NASDAQ: ILMN) was upgraded by analysts at Guggenheim from a "neutral" rating to a "buy" rating. They now have a $345.00 price target on the stock. (9/21/2020)
  • Illumina, Inc. (NASDAQ: ILMN) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. (9/18/2020)
  • Illumina, Inc. (NASDAQ: ILMN) had its "reduce" rating re-affirmed by analysts at Argus. They now have a $380.00 price target on the stock. (9/11/2020)
  • Illumina, Inc. (NASDAQ: ILMN) is now covered by analysts at Morgan Stanley. They set an "equal weight" rating and a $400.00 price target on the stock. (9/9/2020)
#10 - Walgreens Boots Alliance (NASDAQ:WBA)

Number of Downgrades: 13 (in the last 90 days)
Consensus Rating: Hold
Rating Score: 1.9
Ratings Breakdown: 0 Buy Ratings, 14 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: $44.79 (26.4% Upside)

Walgreens Boots Alliance logoWalgreens Boots Alliance, Inc operates as a pharmacy-led health and wellbeing company. It operates through three segments: Retail Pharmacy USA, Retail Pharmacy International, and Pharmaceutical Wholesale. The Retail Pharmacy USA segment sells prescription drugs and an assortment of retail products, including health, beauty, personal care, consumable, and general merchandise products through its retail drugstores and convenient care clinics. Read More 

Recent Recommendations for Walgreens Boots Alliance:

  • Walgreens Boots Alliance Inc (NASDAQ: WBA) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. (9/19/2020)
  • Walgreens Boots Alliance Inc (NASDAQ: WBA) had its price target lowered by analysts at Mizuho from $43.00 to $37.00. They now have a "neutral" rating on the stock. (9/11/2020)
  • Walgreens Boots Alliance Inc (NASDAQ: WBA) had its "hold" rating re-affirmed by analysts at Raymond James. (9/7/2020)
  • Walgreens Boots Alliance Inc (NASDAQ: WBA) had its price target lowered by analysts at Morgan Stanley from $45.00 to $40.00. They now have an "equal weight" rating on the stock. (9/3/2020)
  • Walgreens Boots Alliance Inc (NASDAQ: WBA) had its price target lowered by analysts at Royal Bank of Canada from $45.00 to $38.00. They now have a "sector perform" rating on the stock. (9/2/2020)
  • Walgreens Boots Alliance Inc (NASDAQ: WBA) had its price target lowered by analysts at Credit Suisse Group AG from $45.00 to $42.00. They now have a "neutral" rating on the stock. (8/27/2020)
  • Walgreens Boots Alliance Inc (NASDAQ: WBA) had its price target lowered by analysts at Mizuho from $48.00 to $43.00. They now have a "neutral" rating on the stock. (7/21/2020)
  • Walgreens Boots Alliance Inc (NASDAQ: WBA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong sell" rating. They now have a $42.00 price target on the stock. (7/17/2020)
  • Walgreens Boots Alliance Inc (NASDAQ: WBA) had its price target lowered by analysts at Bank of America Corp from $43.00 to $40.00. They now have an "underperform" rating on the stock. (7/10/2020)
  • Walgreens Boots Alliance Inc (NASDAQ: WBA) had its price target lowered by analysts at Royal Bank of Canada from $48.00 to $45.00. They now have a "sector perform" rating on the stock. (7/10/2020)
#11 - Diamondback Energy (NASDAQ:FANG)

Number of Downgrades: 13 (in the last 90 days)
Consensus Rating: Buy
Rating Score: 2.8
Ratings Breakdown: 23 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $62.91 (110.4% Upside)

Diamondback Energy logoDiamondback Energy, Inc, an independent oil and natural gas company, focuses on the acquisition, development, exploration, and exploitation of unconventional and onshore oil and natural gas reserves in the Permian Basin in West Texas. It primarily focuses on the development of the Spraberry and Wolfcamp formations of the Midland basin; and the Wolfcamp and Bone Spring formations of the Delaware basin, which are part of the Permian Basin in West Texas and New Mexico. Read More 

Recent Recommendations for Diamondback Energy:

  • Diamondback Energy Inc (NASDAQ: FANG) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. (9/25/2020)
  • Diamondback Energy Inc (NASDAQ: FANG) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. (9/19/2020)
  • Diamondback Energy Inc (NASDAQ: FANG) was downgraded by analysts at ValuEngine from a "sell" rating to a "strong sell" rating. (9/9/2020)
  • Diamondback Energy Inc (NASDAQ: FANG) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. (9/3/2020)
  • Diamondback Energy Inc (NASDAQ: FANG) had its price target raised by analysts at Morgan Stanley from $33.00 to $44.00. They now have an "equal weight" rating on the stock. (8/21/2020)
  • Diamondback Energy Inc (NASDAQ: FANG) had its price target lowered by analysts at Wells Fargo & Company from $53.00 to $51.00. They now have an "overweight" rating on the stock. (8/13/2020)
  • Diamondback Energy Inc (NASDAQ: FANG) had its price target raised by analysts at Piper Sandler from $58.00 to $64.00. They now have an "overweight" rating on the stock. (8/13/2020)
  • Diamondback Energy Inc (NASDAQ: FANG) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. (8/12/2020)
  • Diamondback Energy Inc (NASDAQ: FANG) is now covered by analysts at Credit Suisse Group AG. They set a "buy" rating and a $57.00 price target on the stock. (8/4/2020)
  • Diamondback Energy Inc (NASDAQ: FANG) was downgraded by analysts at TheStreet from a "c" rating to a "d" rating. (8/3/2020)
#12 - BioMarin Pharmaceutical (NASDAQ:BMRN)

Number of Downgrades: 13 (in the last 90 days)
Consensus Rating: Buy
Rating Score: 2.6
Ratings Breakdown: 13 Buy Ratings, 10 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $119.88 (54.9% Upside)

BioMarin Pharmaceutical logoBioMarin Pharmaceutical Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. Read More 

Recent Recommendations for BioMarin Pharmaceutical:

  • BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. (9/19/2020)
  • BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Truist from $130.00 to $125.00. (9/10/2020)
  • BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "buy" rating re-affirmed by analysts at Wedbush. (9/10/2020)
  • BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Morgan Stanley from $125.00 to $85.00. They now have an "equal weight" rating on the stock. (8/21/2020)
  • BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Truist from $143.00 to $130.00. (8/20/2020)
  • BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $116.00 to $88.00. (8/20/2020)
  • BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Canaccord Genuity from $119.00 to $95.00. They now have a "buy" rating on the stock. (8/20/2020)
  • BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Jefferies Financial Group Inc from $138.00 to $118.00. They now have a "buy" rating on the stock. (8/20/2020)
  • BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "market perform" rating re-affirmed by analysts at William Blair. (8/20/2020)
  • BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was downgraded by analysts at Citigroup Inc from a "buy" rating to a "neutral" rating. They now have a $86.00 price target on the stock, down previously from $148.00. (8/19/2020)
#13 - Unity Biotechnology (NASDAQ:UBX)

Number of Downgrades: 12 (in the last 90 days)
Consensus Rating: Hold
Rating Score: 2.3
Ratings Breakdown: 2 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $7.00 (97.7% Upside)

Unity Biotechnology logoUnity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 that is in Phase 1 clinical study for musculoskeletal disease; and UBX1967 for ophthalmologic diseases. It is also developing programs in pulmonary disorders. Read More 

Recent Recommendations for Unity Biotechnology:

  • Unity Biotechnology Inc (NASDAQ: UBX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. (9/9/2020)
  • Unity Biotechnology Inc (NASDAQ: UBX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. (9/2/2020)
  • Unity Biotechnology Inc (NASDAQ: UBX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. (8/27/2020)
  • Unity Biotechnology Inc (NASDAQ: UBX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.50 price target on the stock. (8/26/2020)
  • Unity Biotechnology Inc (NASDAQ: UBX) had its "buy" rating re-affirmed by analysts at Mizuho. (8/24/2020)
  • Unity Biotechnology Inc (NASDAQ: UBX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. (8/21/2020)
  • Unity Biotechnology Inc (NASDAQ: UBX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.75 price target on the stock. (8/20/2020)
  • Unity Biotechnology Inc (NASDAQ: UBX) had its price target lowered by analysts at Goldman Sachs Group Inc from $8.00 to $4.00. They now have a "neutral" rating on the stock. (8/18/2020)
  • Unity Biotechnology Inc (NASDAQ: UBX) was downgraded by analysts at Citigroup Inc from a "buy" rating to a "neutral" rating. They now have a $5.00 price target on the stock, down previously from $31.00. (8/18/2020)
  • Unity Biotechnology Inc (NASDAQ: UBX) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating. They now have a $5.00 price target on the stock, down previously from $13.00. (8/18/2020)
#14 - Akebia Therapeutics (NASDAQ:AKBA)

Number of Downgrades: 11 (in the last 90 days)
Consensus Rating: Buy
Rating Score: 2.6
Ratings Breakdown: 4 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $10.43 (320.5% Upside)

Akebia Therapeutics logoAkebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients. Read More 

Recent Recommendations for Akebia Therapeutics:

  • Akebia Therapeutics Inc (NASDAQ: AKBA) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. (9/22/2020)
  • Akebia Therapeutics Inc (NASDAQ: AKBA) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. (9/15/2020)
  • Akebia Therapeutics Inc (NASDAQ: AKBA) had its "buy" rating re-affirmed by analysts at Zacks Investment Research. They now have a $6.00 price target on the stock, down previously from $17.00. (9/4/2020)
  • Akebia Therapeutics Inc (NASDAQ: AKBA) had its price target lowered by analysts at Morgan Stanley from $12.00 to $3.00. They now have an "equal weight" rating on the stock. (9/4/2020)
  • Akebia Therapeutics Inc (NASDAQ: AKBA) had its price target lowered by analysts at BTIG Research from $26.00 to $6.00. They now have a "buy" rating on the stock. (9/4/2020)
  • Akebia Therapeutics Inc (NASDAQ: AKBA) had its price target lowered by analysts at HC Wainwright from $17.00 to $10.00. They now have a "buy" rating on the stock. (9/4/2020)
  • Akebia Therapeutics Inc (NASDAQ: AKBA) had its price target lowered by analysts at Mizuho from $17.00 to $6.00. They now have a "buy" rating on the stock. (9/4/2020)
  • Akebia Therapeutics Inc (NASDAQ: AKBA) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. (9/3/2020)
  • Akebia Therapeutics Inc (NASDAQ: AKBA) was downgraded by analysts at JPMorgan Chase & Co. from an "overweight" rating to a "neutral" rating. (9/3/2020)
  • Akebia Therapeutics Inc (NASDAQ: AKBA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. (8/14/2020)
#15 - Seagate Technology (NASDAQ:STX)

Number of Downgrades: 11 (in the last 90 days)
Consensus Rating: Hold
Rating Score: 2.1
Ratings Breakdown: 6 Buy Ratings, 13 Hold Ratings, 4 Sell Ratings.
Consensus Price Target: $52.68 (9.3% Upside)

Seagate Technology logoSeagate Technology plc provides data storage technology and solutions in Singapore, the United States, the Netherlands, and internationally. It manufactures and distributes hard disk drives; solid state drives (SSDs), including serial attached small computer system interface and non-volatile memory express SSDs; solid state hybrid drives; and storage subsystems. Read More 

Recent Recommendations for Seagate Technology:

  • Seagate Technology PLC (NASDAQ: STX) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. They now have a $52.00 price target on the stock. (9/18/2020)
  • Seagate Technology PLC (NASDAQ: STX) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. (9/17/2020)
  • Seagate Technology PLC (NASDAQ: STX) had its "buy" rating re-affirmed by analysts at Rosenblatt Securities. (9/17/2020)
  • Seagate Technology PLC (NASDAQ: STX) is now covered by analysts at Northland Securities. They set an "outperform" rating and a $65.00 price target on the stock. (9/15/2020)
  • Seagate Technology PLC (NASDAQ: STX) was upgraded by analysts at ValuEngine from a "strong sell" rating to a "sell" rating. (8/13/2020)
  • Seagate Technology PLC (NASDAQ: STX) was upgraded by analysts at UBS Group AG from a "sell" rating to a "neutral" rating. They now have a $46.00 price target on the stock, up previously from $41.00. (8/4/2020)
  • Seagate Technology PLC (NASDAQ: STX) had its "hold" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $48.00 price target on the stock. (7/30/2020)
  • Seagate Technology PLC (NASDAQ: STX) had its price target lowered by analysts at Bank of America Corp from $45.00 to $43.00. They now have an "underperform" rating on the stock. (7/29/2020)
  • Seagate Technology PLC (NASDAQ: STX) had its "sell" rating re-affirmed by analysts at Susquehanna Bancshares Inc. They now have a $33.00 price target on the stock. (7/29/2020)
  • Seagate Technology PLC (NASDAQ: STX) had its price target lowered by analysts at Morgan Stanley from $56.00 to $55.00. They now have an "overweight" rating on the stock. (7/29/2020)
#16 - Ciena (NYSE:CIEN)

Number of Downgrades: 11 (in the last 90 days)
Consensus Rating: Buy
Rating Score: 2.8
Ratings Breakdown: 18 Buy Ratings, 3 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: $54.25 (38.0% Upside)

Ciena logoCiena Corporation provides network hardware, software, and services that support the transport, switching, aggregation, service delivery, and management of video, data, and voice traffic on communications networks worldwide. The company's Networking Platforms segment offers hardware networking solutions optimized for the convergence of coherent optical transport, optical transport network switching, and packet switching. Read More 

Recent Recommendations for Ciena:

  • Ciena Co. (NYSE: CIEN) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. They now have a $41.00 price target on the stock. (9/24/2020)
  • Ciena Co. (NYSE: CIEN) had its price target lowered by analysts at Raymond James from $55.00 to $50.00. They now have an "outperform" rating on the stock. (9/17/2020)
  • Ciena Co. (NYSE: CIEN) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. They now have a $45.00 price target on the stock. (9/10/2020)
  • Ciena Co. (NYSE: CIEN) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. (9/5/2020)
  • Ciena Co. (NYSE: CIEN) had its price target lowered by analysts at Barclays PLC from $67.00 to $54.00. They now have an "overweight" rating on the stock. (9/4/2020)
  • Ciena Co. (NYSE: CIEN) had its price target lowered by analysts at Morgan Stanley from $50.00 to $46.00. They now have an "equal weight" rating on the stock. (9/4/2020)
  • Ciena Co. (NYSE: CIEN) had its "buy" rating re-affirmed by analysts at Colliers Secur.. (9/4/2020)
  • Ciena Co. (NYSE: CIEN) had its price target lowered by analysts at Citigroup Inc from $65.00 to $55.00. They now have a "buy" rating on the stock. (9/4/2020)
  • Ciena Co. (NYSE: CIEN) had its price target lowered by analysts at MKM Partners from $62.00 to $55.00. They now have a "buy" rating on the stock. (9/4/2020)
  • Ciena Co. (NYSE: CIEN) had its price target lowered by analysts at Rosenblatt Securities from $64.00 to $55.00. They now have a "buy" rating on the stock. (9/4/2020)
#17 - Lumentum (NASDAQ:LITE)

Number of Downgrades: 11 (in the last 90 days)
Consensus Rating: Buy
Rating Score: 2.8
Ratings Breakdown: 15 Buy Ratings, 2 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: $101.28 (36.5% Upside)

Lumentum logoLumentum Holdings Inc manufactures and sells optical and photonic products in the Americas, the Asia-Pacific, Europe, the Middle East, and Africa. The company operates through two segments, Optical Communications and Commercial Lasers. The Optical Communications segment offers components, modules, and subsystems that enable the transmission and transport of video, audio, and text data over high-capacity fiber optic cables. Read More 

Recent Recommendations for Lumentum:

  • Lumentum Holdings Inc (NASDAQ: LITE) had its price target lowered by analysts at B. Riley from $109.00 to $99.00. They now have a "buy" rating on the stock. (9/24/2020)
  • Lumentum Holdings Inc (NASDAQ: LITE) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. (9/22/2020)
  • Lumentum Holdings Inc (NASDAQ: LITE) had its price target lowered by analysts at Raymond James from $98.00 to $90.00. They now have an "outperform" rating on the stock. (9/18/2020)
  • Lumentum Holdings Inc (NASDAQ: LITE) had its price target lowered by analysts at Barclays PLC from $105.00 to $90.00. They now have an "overweight" rating on the stock. (9/16/2020)
  • Lumentum Holdings Inc (NASDAQ: LITE) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. (9/12/2020)
  • Lumentum Holdings Inc (NASDAQ: LITE) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. (9/3/2020)
  • Lumentum Holdings Inc (NASDAQ: LITE) had its price target lowered by analysts at Stifel Nicolaus from $105.00 to $98.00. They now have a "buy" rating on the stock. (9/1/2020)
  • Lumentum Holdings Inc (NASDAQ: LITE) was downgraded by analysts at TheStreet from a "b" rating to a "c+" rating. (8/31/2020)
  • Lumentum Holdings Inc (NASDAQ: LITE) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. (8/27/2020)
  • Lumentum Holdings Inc (NASDAQ: LITE) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. (8/18/2020)
#18 - Veritone (NASDAQ:VERI)

Number of Downgrades: 11 (in the last 90 days)
Consensus Rating: Buy
Rating Score: 2.6
Ratings Breakdown: 4 Buy Ratings, 0 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: $12.60 (49.8% Upside)

Veritone logoVeritone, Inc provides artificial intelligence (AI) and computing solutions in the United States and the United Kingdom. It develops and operates aiWARE platform, an AI operating system that unlocks the power of cognitive computing to transform audio, video, and other unstructured data, as well as analyzes it in conjunction with structured data in an orchestrated and automated manner to generate actionable intelligence. Read More 

Recent Recommendations for Veritone:

  • Veritone Inc (NASDAQ: VERI) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. (9/25/2020)
  • Veritone Inc (NASDAQ: VERI) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. (9/3/2020)
  • Veritone Inc (NASDAQ: VERI) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. (9/1/2020)
  • Veritone Inc (NASDAQ: VERI) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. (8/27/2020)
  • Veritone Inc (NASDAQ: VERI) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $10.00 price target on the stock. (8/26/2020)
  • Veritone Inc (NASDAQ: VERI) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. (8/26/2020)
  • Veritone Inc (NASDAQ: VERI) had its "buy" rating re-affirmed by analysts at Roth Capital. (8/24/2020)
  • Veritone Inc (NASDAQ: VERI) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. (8/15/2020)
  • Veritone Inc (NASDAQ: VERI) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $15.00 price target on the stock. (8/14/2020)
  • Veritone Inc (NASDAQ: VERI) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $14.00 price target on the stock. (8/8/2020)
#19 - Childrens Place (NASDAQ:PLCE)

Number of Downgrades: 11 (in the last 90 days)
Consensus Rating: Hold
Rating Score: 2.3
Ratings Breakdown: 4 Buy Ratings, 6 Hold Ratings, 1 Sell Ratings.
Consensus Price Target: $35.36 (29.1% Upside)

Childrens Place logoThe Children's Place, Inc operates as a children's specialty apparel retailer. The company operates through two segments, The Children's Place U.S. and The Children's Place International. It sells apparel, footwear, accessories, and other items for children; and designs, contracts to manufacture, and sells merchandise under the proprietary The Children's Place, Place, and Baby Place brand names. Read More 

Recent Recommendations for Childrens Place:

  • Childrens Place Inc (NASDAQ: PLCE) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. (9/17/2020)
  • Childrens Place Inc (NASDAQ: PLCE) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. (9/5/2020)
  • Childrens Place Inc (NASDAQ: PLCE) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. (9/1/2020)
  • Childrens Place Inc (NASDAQ: PLCE) had its price target lowered by analysts at B. Riley from $29.00 to $20.00. (8/26/2020)
  • Childrens Place Inc (NASDAQ: PLCE) had its price target lowered by analysts at DA Davidson from $42.00 to $20.00. They now have a "neutral" rating on the stock. (8/26/2020)
  • Childrens Place Inc (NASDAQ: PLCE) had its price target lowered by analysts at Monness Crespi & Hardt from $55.00 to $35.00. They now have a "buy" rating on the stock. (8/26/2020)
  • Childrens Place Inc (NASDAQ: PLCE) had its price target lowered by analysts at Telsey Advisory Group from $55.00 to $35.00. They now have an "outperform" rating on the stock. (8/26/2020)
  • Childrens Place Inc (NASDAQ: PLCE) had its price target lowered by analysts at Barclays PLC from $43.00 to $18.00. They now have an "equal weight" rating on the stock. (8/26/2020)
  • Childrens Place Inc (NASDAQ: PLCE) had its price target lowered by analysts at Citigroup Inc from $46.00 to $20.00. They now have a "neutral" rating on the stock. (8/26/2020)
  • Childrens Place Inc (NASDAQ: PLCE) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. (8/26/2020)
#20 - FirstEnergy (NYSE:FE)

Number of Downgrades: 11 (in the last 90 days)
Consensus Rating: Hold
Rating Score: 2.5
Ratings Breakdown: 7 Buy Ratings, 8 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $42.03 (47.0% Upside)

FirstEnergy logoFirstEnergy Corp., through its subsidiaries, generates, transmits, and distributes electricity in the United States. The company operates through Regulated Distribution and Regulated Transmission segments. It owns and operates coal-fired, nuclear, hydroelectric, natural gas, wind, and solar power generating facilities. Read More 

Recent Recommendations for FirstEnergy:

  • FirstEnergy Corp. (NYSE: FE) was upgraded by analysts at Royal Bank of Canada from a "sector perform" rating to an "outperform" rating. They now have a $37.00 price target on the stock, up previously from $36.00. (9/3/2020)
  • FirstEnergy Corp. (NYSE: FE) had its price target lowered by analysts at Morgan Stanley from $43.00 to $40.00. They now have an "overweight" rating on the stock. (8/14/2020)
  • FirstEnergy Corp. (NYSE: FE) had its price target lowered by analysts at Mizuho from $45.00 to $28.50. They now have a "neutral" rating on the stock. (8/4/2020)
  • FirstEnergy Corp. (NYSE: FE) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. (8/3/2020)
  • FirstEnergy Corp. (NYSE: FE) had its price target lowered by analysts at Morgan Stanley from $47.00 to $43.00. They now have an "overweight" rating on the stock. (7/28/2020)
  • FirstEnergy Corp. (NYSE: FE) had its price target raised by analysts at Bank of America Corp from $36.50 to $37.00. They now have a "buy" rating on the stock. (7/27/2020)
  • FirstEnergy Corp. (NYSE: FE) was downgraded by analysts at Scotiabank from a "sector outperform" rating to a "sector perform" rating. They now have a $39.00 price target on the stock, down previously from $53.00. (7/22/2020)
  • FirstEnergy Corp. (NYSE: FE) had its price target lowered by analysts at Wells Fargo & Company from $50.00 to $40.00. They now have an "overweight" rating on the stock. (7/22/2020)
  • FirstEnergy Corp. (NYSE: FE) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating. They now have a $36.00 price target on the stock, down previously from $51.00. (7/22/2020)
  • FirstEnergy Corp. (NYSE: FE) was downgraded by analysts at Evercore ISI from an "outperform" rating to an "in-line" rating. They now have a $41.00 price target on the stock, down previously from $50.00. (7/22/2020)

 

8 Artificial Intelligence Stocks That Will Make You Feel Like a Smart Investor

In 2018, it was cannabis. In 2019, it was 5G. And yet before either of those trends, artificial intelligence (or AI) was growing relentlessly and undeniably.

Artificial intelligence stems from the simple fact that computers are getting smarter. And they are being designed to process information faster. The words “machine learning” are being used to summarize the creation of algorithms, freed from human programmers, which train themselves on massive data sets. Earlier this year, two separate artificial intelligence “machines” demonstrated the ability to “read” Wikipedia entries and answer questions better than humans did.

But AI is more than a parlor trick. Chances are at some point today, you’ve experienced a benefit of artificial intelligence. You may have gotten to this page because of an internet search. You may have asked Alexa or your Google Assistant to perform a command. You may have voice-activated your Roomba vacuum. You may have used an AI-powered GPS system to get to wherever you’re reading this.

In the future, you may be hailing an autonomous car. A virtual assistant will be able to place calls for you to make appointments. But instead of sounding like a robot, the assistant will sound human, with an understanding of context and nuance. And those are just two applications. There will be more because the possibilities of artificial intelligence are expansive. But they can also be somewhat chilling. Many of the functions that are performed by humans today may be made obsolete by AI. But that’s a subject for another day.

Right now, you want to know how you can profit from this emerging trend.

You’ve come to the right place. In this special presentation, we will take a look at 8 stocks that can help you profit from the artificial intelligence trend.

View the "8 Artificial Intelligence Stocks That Will Make You Feel Like a Smart Investor" Here.






Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.